Veracyte, Inc.
VCYT
Classifica tra le azioni
#4356
Veracyte, Inc. operates as a diagnostics company in the United States and... Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Prezzo delle azioni
$44.68
Capitalizzazione di mercato
$3.59B
Variazione (1 giorno)
2.01%
Variazione (1 anno)
21.91%
Paese
US
Scambia Veracyte, Inc. (VCYT)
Categoria
Healthcare
Rapporto P/S per Veracyte, Inc. (VCYT)
Rapporto P/S al October 2026 TTM: 6.22
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Veracyte, Inc., il rapporto P/S attuale (TTM) è 6.22. Alla fine del 2023, era pari a 5.54.
Storico del rapporto P/S per Veracyte, Inc. da 2011 a 2026
Rapporto P/S alla fine di ogni anno
| Anno | Rapporto P/S | Cambia |
|---|---|---|
| 2026 (TTM) | 6.22 | -8.32% |
| 2024 | 6.79 | 22.75% |
| 2023 | 5.54 | -3.33% |
| 2022 | 5.73 | -55.07% |
| 2021 | 12.74 | -42.55% |
| 2020 | 22.18 | 107.23% |
| 2019 | 10.70 | 111.43% |
| 2018 | 5.06 | 64.40% |
| 2017 | 3.08 | -10.20% |
| 2016 | 3.43 | -9.14% |
| 2015 | 3.77 | -31.06% |
| 2014 | 5.47 | 98.64% |
| 2013 | 2.76 | -82.96% |
| 2012 | 16.18 | -77.25% |
| 2011 | 71.11 | 0.00% |
Rapporto P/S per aziende simili o concorrenti
| Azienda | Rapporto P/S | Differenza del rapporto P/S | Il paese |
|---|---|---|---|
| 5.37 | -13.70% |
US
|
|
| 6.29 | 1.08% |
US
|
|
| 21.02 | 237.66% |
US
|
|
| - | - |
CN
|
|
| 6.67 | 7.09% |
US
|
